Sandra Levy
ARTICLES BY THIS AUTHOR
- 9/27/2021
Impel NeuroPharma intros migraine treatment Trudhesa
Trudhesa is launching with an end-to-end process meant to offer savings and home delivery of the treatment for acute migraines. - 9/26/2021
Hikma to acquire Custopharm
Custopharm, a generic sterile injectables company, markets its products through Leucadia Pharmaceuticals. - 9/26/2021
Zydus Cadila gets FDA blessing for generic Otezla
Zydus Cadila’s generic Otezla provides treatment for adults with moderate to severe plaque psoriasis. - 9/26/2021
Schnucks to award 4th bonus to front-line employees
Schnucks teammates who qualify could receive up to $600 in a one-time bonus, paying out in January 2022. - 9/23/2021
Aurobindo obtains FDA nod for generic Tricor
Aurobindo's fenofibrate capsules will be available in dosage strengths of 67 mg, 134 mg and 200 mg. - 9/23/2021
CDC director overrules agency's advisors on COVID-19 boosters
Centers for Disease Control and Prevention director Rochelle Walensky overruled her agency advisory panel by recommending COVID-19 boosters for people at risk of the coronavirus because of their jobs. - 9/22/2021
Incyte wins FDA nod for Opzelura
Opzelura is the first and only topical formulation of a Janus kinase inhibitor approved in the United States. - 9/22/2021
Glenmark gets FDA green light for generic Evoclin
Evoclin Foam had a market value of approximately $12 million for the 12 months endedJuly 2021, according to IQVIA. - 9/22/2021
FDA OKs Pfizer's COVID-19 vaccine booster for older adults, people at high risk
The Food and Drug Administration granted an emergency use authorization for the booster in individuals age 65 years old and older, and individuals age 18 to 64 years old within certain high-risk groups. - 9/21/2021
Scynexis debuts Brexafemme
Brexafemme is the first and only oral non-azole prescription medication approved by the FDA to treat vaginal yeast infection.
